Tirzepatide 5 mg is a once‑weekly maintenance dose used after 4 weeks at 2.5 mg to improve blood sugar in adults with type 2 diabetes and for chronic weight management under brand labeling, with further titration in 2.5 mg steps if needed. For obesity treatment (Zepbound), 5 mg is an approved maintenance dose option alongside 10 mg and 15 mg, selected based on response and tolerability. It’s also part of the titration pathway for obstructive sleep apnea associated with obesity, though OSA maintenance doses are typically 10–15 mg weekly. Dose increases require at least 4 weeks between steps.